The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis
Abstract
Objective. —To examine more closely the association between apolipoprotein E (APOE) genotype and Alzheimer disease (AD) by age and sex in populations of various ethnic and racial denominations. Data Sources. —Forty research teams contributed data onAPOEgenotype, sex, age at disease onset, and ethnic background for 5930 patients who met criteria for probable or definite AD and 8607 controls without dementia who were recruited from clinical, community, and brain bank sources. Main Outcome Measures. —Odds ratios (ORs) and 95% confidence intervals (Cls) for AD, adjusted for age and study and stratified by major ethnic group (Caucasian, African American, Hispanic, and Japanese) and source, were computed forAPOEgenotypes ∈2/∈2,∈2/∈3,∈2/∈4,∈3/∈4 and ∈4/∈4 relative to the ∈3/∈3 group. The influence of age and sex on the OR for each genotype was assessed using logistic regression procedures. Results. —Among Caucasian subjects from clinic- or autopsy-based studies, the risk of AD was significantly increased for people with genotypes ∈2/∈4 (OR=2.6, 95% Cl=1.6-4.0), ∈3/∈4 (OR=3.2, 95% Cl=2.8-3.8), and ∈4/∈4 (OR=14.9, 95% CI=10.8-20.6); whereas, the ORs were decreased for people with genotypes ∈2/∈2 (OR=0.6, 95% Cl=0.2-2.0) and ∈2/∈3 (OR=0.6, 95% Cl=0.5-0.8). TheAPOE∈4-AD association was weaker among African Americans and Hispanics, but there was significant heterogeneity in ORs among studies of African Americans (P<.03). TheAPOE∈4—AD association in Japanese subjects was stronger than in Caucasian subjects (∈3/∈4: OR=5.6, 95% Cl=3.9-8.0; ∈4/∈4: OR=33.1, 95% Cl=13.6-80.5). The ∈2/∈3 genotype appears equally protective across ethnic groups. We also found that among Caucasians,APOEgenotype distributions are similar in groups of patients with AD whose diagnoses were determined clinically or by autopsy. In addition, we found that theAPOE∈4 effect is evident at all ages between 40 and 90 years but diminishes after age 70 years and that the risk of AD associated with a given genotype varies with sex. Conclusions. —TheAPOE∈4 allele represents a major risk factor for AD in all ethnic groups studied, across all ages between 40 and 90 years, and in both men and women. The association betweenAPOE∈4 and AD in African Americans requires clarification, and the attenuated effect ofAPOE∈4 in Hispanics should be investigated further.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The greatest risk factors for late-onset Alzheimer's are older age, 62,63 genetics 64,65 -especially the e4 form of the apolipoprotein E (APOE) gene -and having a family history of Alzheimer's.[66][67][68][69]”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [65]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“Also, previous studies of clinically and neuropathologically characterized cases and controls may have been too small to demonstrate that APOE2 homozygotes have an even lower OR than the relatively low-risk APOE2/3 group due to the paucity of APOE2 homozygotes, who comprise <1% of the general population1,4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“Fourth, findings from our non-Hispanic White groups cannot yet be extended to other ethnic and racial groups4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [4]
In the citing paper
“APOE is genetically linked to late-onset sporadic Alzheimer’s disease (LOAD), with APOE4 being a significant risk factor, APOE3 considered the “neutral” allele, and APOE2 exerting a protective role against LOAD [6, 7].”
In the citing paper
“In addition, APOE4 is linked to hypercholesterolemia and increased risk of cardiovascular disorders (CVD) [7, 41]”
In the citing paper
“Compared to ε3 homozygotes, individuals with one or two ε4 alleles harbor approximately 3 and 15 times increased risk, respectively”
From Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status (2024) · cites this paper as [1]
In the citing paper
“whereas carriers of the protective ε2 allele have an estimated 1.7 times decreased risk [1]”
From Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status (2024) · cites this paper as [1]
In the citing paper
“Between 45% and 50% of AD patients carry at least one APOE4 allele compared to only 15% of age-matched healthy controls.5,11”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [11]
In the citing paper
“APOE4 is the strongest genetic determinant of late-onset AD, increasing risk in a gene dose-dependent manner, whereas APOE2 confers substantial protection 1 -5 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [5]
In the citing paper
“In humans, the APOE2/4 genotype confers an intermediate risk, higher than that of APOE3/3 but lower than APOE3/4 and APOE4/4 5,6 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [5]
In the citing paper
“Population studies have demonstrated that the ε4 allele increases the risk of developing AD by either 3-fold (1 allele) or 12-fold (2 alleles) [6]”
From In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS (2012) · cites this paper as [6]
In the citing paper
“ApoE4, found in 65–80% of cases of sporadic and familial Alzheimer's disease, increases the occurrence of AD by ∼12 fold in two ɛ4 allele carriers, compared with those with no ɛ4 allele (Farrer et al., 1997).”
From Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms (2014) · cites this paper as Farrer et al., 1997
In the citing paper
“The APOE4 allele is a major genetic risk factor for late-onset AD and was previously shown to accelerate AD progression in humans and in mouse models 6-11 .”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as [6]
In the citing paper
“The APOE4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease (AD).”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as [6]
In the citing paper
“Epidemiologic studies show sex differences in clinical risk are largely discernable within the context of APOE ε4,11,42,43 particularly between the ages of 65 to 75 years compared with APOE ε4 clinically normal male carriers.44”
From Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults (2019) · cites this paper as [43]
In the citing paper
“Separately, clinical studies have reported that women APOE ε4 carriers had a higher risk of Alzheimer’s dementia than men carriers [21].”
From Sex differences in Alzheimer’s disease and common neuropathologies of aging (2018) · cites this paper as [21]
In the citing paper
“Furthermore, a recent meta-analysis of 58000 participants showed that APOE ε3/ε4 women have the same increased odds of AD dementia as APOE ε3ε4 men have, in contrast to a previous meta-analysis which reported APOE ε4 women to carry a higher risk of Alzheimer’s dementia compared to APOE ε4 men [21].”
From Sex differences in Alzheimer’s disease and common neuropathologies of aging (2018) · cites this paper as [21]
In the citing paper
“As APOE4 carriers make up 55–75% of AD cases17–20”
From The APOE-R136S mutation protects against APOE4-driven tau pathology, neurodegeneration, and neuroinflammation (2023) · cites this paper as [18]
In the citing paper
“The initial intriguing observation that the APOEε4 allele increases AD risk differentially across races and ethnicities, with the greatest increase in risk seen in East Asian people, followed by white, then Black, then Hispanic people6, has now been confirmed by a larger meta-analysis using not only self-reported race and ethnicity but also global genetic ancestry to ascertain the biological basis”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [6]
In the citing paper
“Rather, age and sex moderate the effects of the APOE genotype on AD risk so that the risk associated with the APOEε3/ε4 genotype is highest in women of ages 60–70 years (or 70–80 years according to ref. 6) but decreases in older women and equalizes to that of non-Hispanic White, Black and Hispanic men of the same age10.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [6]
In the citing paper
“The APOE polymorphism is the most studied, successfully replicated, and well-established risk factor for AD where APOE*2 is the protective allele and APOE*4 is the risk allele as compared to APOE*3 [7–10].”
From Genome-wide analysis identifies novel loci influencing plasma apolipoprotein E concentration and Alzheimer’s disease risk (2023) · cites this paper as [8]
In the citing paper
“The original association study implicating L28P with LOAD risk was carried out in a relatively small sample size.”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [9]
In the citing paper
“due to the complete linkage disequilibrium of L28P with APOE*4 (C112R)”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [9]
In the citing paper
“it was associated with an elevated risk for AD [9]”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [9]
In the citing paper
“In 1999, two groups independently identified a novel and rare missense mutation in the APOE gene [9, 10] in which the leucine residue is replaced by proline at codon 28 (L28P; rs769452).”
From Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late-onset Alzheimer disease (2023) · cites this paper as [9]
In the citing paper
“with the East Asian population having a higher risk of AD associated with the APOE ε4 allele”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [11]
In the citing paper
“while the effect of APOE ε4 is weaker in African American and Hispanic populations”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [11]
In the citing paper
“The AD risk associated with common APOE alleles ε4 1 and ε2 2 is well established in European-ancestry individuals but varies considerably across other ancestries (Table 1). 3”
From Association of African Ancestry–Specific APOE Missense Variant R145C With Risk of Alzheimer Disease (2023) · cites this paper as [3]
In the citing paper
“Among the AD susceptibility genes/loci identified to date, APOE remains the most significant genetic risk factor across populations.”
From Association of rare APOE missense variants with Alzheimer's disease in the Japanese population (2025) · cites this paper as [8]
In the citing paper
“Although there is only about 20% of the population carrying the APOE ε4, this isoform is vastly enriched in AD patients with over 60% of symptomatic AD patients carrying at least one APOE ε4 allele”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Farrer et al 1997
In the citing paper
“The ε4 allele of apolipoprotein E (APOE) is the dominant genetic risk factor for late-onset Alzheimer’s disease (AD).”
From APOE4 is Associated with Differential Regional Vulnerability to Bioenergetic Deficits in Aged APOE Mice (2020) · cites this paper as [5]
In the citing paper
“The genetic polymorphism of human apolipoprotein E (ApoE) has been shown to confer differential susceptibility to late-onset AD, which accounts for the majority of the AD cases (Farrer et al., 1997).”
From Human ApoE Isoforms Differentially Modulate Brain Glucose and Ketone Body Metabolism: Implications for Alzheimer's Disease Risk Reduction and Early Intervention (2018) · cites this paper as Farrer et al., 1997
In the citing paper
“occurs in approximately two-thirds of all cases [1–3]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [2]
In the citing paper
“Apolipoprotein (apo) E4 is the major genetic risk factor for Alzheimer’s disease (AD)”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [2]
In the citing paper
“In contrast, APOE3 is defined as risk-neutral while APOE2 represents the strongest genetic protective factor (Corder et al., 1994; Farrer et al., 1997; Reiman et al., 2020).”
From APOE genotype-dependent differences in human astrocytic energy metabolism (2025) · cites this paper as Farrer et al., 1997
In the citing paper
“Since then, numerous studies have confirmed that possession of the ε4 allele is the strongest genetic risk factor for both AD and CAA, or a combination of both disorders (Bertram et al., 2007; Farrer et al., 1997).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Farrer et al., 1997
In the citing paper
“However, in certain ethnic groups, the apoE ε4 allele seems to have either a weaker effect or no clear effect on AD (Farrer et al., 1997; Kalaria et al., 2008; Mayeux, 2003; Tang et al., 1998).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Farrer et al., 1997
In the citing paper
“Finally, it is important to note that the ε2 allele of apoE is associated with a lower risk for AD (Corder et al., 1994; Farrer et al., 1997).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Farrer et al., 1997
In the citing paper
“APOE genotypes were in Hardy-Weinberg equilibrium in both cases and controls; their frequencies (Table 4) were similar to previous reports for the relevant age groups (44;47;48).”
From Association of ALS with head injury, cigarette smoking and APOE genotypes (2010) · cites this paper as [47]
In the citing paper
“The ε4 allele of apolipoprotein E (APOE) is the strongest genetic risk factor for sporadic Alzheimer's Disease (AD).”
From APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer’s disease pathology (2024) · cites this paper as [4]
In the citing paper
“An APOE ε4/ε4 individual of European ancestry has a sixteen-fold increase in AD risk and eighteen year earlier age at AD onset compared to a European ancestry individual carrying two copies of the more prevalent APOE ε3 allele 4 .”
From APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer’s disease pathology (2024) · cites this paper as [4]
In the citing paper
“The global frequency of the human ε4 allele is 13.7%, and the frequency of ε4 carriers is increased to 40% in AD patients [452, 453].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [453]
In the citing paper
“Clinical incidence and average age of AD onset was found to be 91% at 68 years of age in ε4 homozygous carriers, 47% at 76 years of age in ε4 heterozygous carriers, and 20% at 84 years of age in non-ε4 individuals [453].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [453]
In the citing paper
“ApoE4 is present in roughly 20–25% of the human population, and apoE4 carriers account for 60–75% of AD cases in most clinical studies [11], highlighting the importance of apoE4 in AD pathogenesis.”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [11]
In the citing paper
“ApoE4 increases the risk and decreases the age of onset of AD in a gene dose dependent manner [4–11].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [11]
In the citing paper
“the effect of APOEε4 has been reported to differ across ethnicities [58–61]”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [58]
In the citing paper
“the association between ε4 and disease is reported to be weaker among African-American and Hispanic individuals [58, 61, 62] and nonexistent among Nigerian individuals [63].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [58]
In the citing paper
“APOEε2/APOEε4 individuals are still at increased risk for AD, suggesting the APOEε4 isoform exhibits some dominant effect over the APOEε2 isoform [58].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [58]
In the citing paper
“Several studies have demonstrated APOE genotype has an exacerbated effect on disease risk in females [58]”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [58]
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Cited by
Sorted by citations
Items 1,001–1,100 of 1,178
Relation of genomic variants for Alzheimer disease dementia to common neuropathologies
Farfel, J. M., Yu, L., Buchman, A. S., Schneider, J. A., De Jager, P. L., & Bennett, D. A. (2016) · Neurology · doi:10.1212/wnl.0000000000002909 · Cited by 64
Using genetics to enable studies on the prevention of Alzheimer's disease
Crenshaw, D. G., Gottschalk, W. K., Lutz, M. W., Grossman, I., Saunders, A. M., Burke, J. R., Welsh-Bohmer, K. A., Brannan, S. K., Burns, D. K., & Roses, A. D. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.222 · Cited by 70
Granot‐Hershkovitz, E., Tarraf, W., Kurniansyah, N., Daviglus, M., Isasi, C. R., Kaplan, R., Lamar, M., Perreira, K. M., Wassertheil‐Smoller, S., Stickel, A., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12205 · Cited by 71
Mak, E., Gabel, S., Mirette, H., Su, L., Williams, G. B., Waldman, A., Wells, K., Ritchie, K., Ritchie, C., & O’Brien, J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.10.001 · Cited by 71
D’Cunha, N. M., Georgousopoulou, E. N., Dadigamuwage, L., Kellett, J., Panagiotakos, D. B., Thomas, J., McKune, A. J., Mellor, D. D., & Naumovski, N. (2018) · British Journal of Nutrition · doi:10.1017/s0007114517003452 · Cited by 68
Elias-Sonnenschein, L. S., Helisalmi, S., Natunen, T., Hall, A., Paajanen, T., Herukka, S.-K., Laitinen, M., Remes, A. M., Koivisto, A. M., Mattila, K. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059676 · Cited by 70
PLXNA4 is associated with Alzheimer disease and modulates tau phosphorylation
Jun, G., Asai, H., Zeldich, E., Drapeau, E., Chen, C., Chung, J., Park, J., Kim, S., Haroutunian, V., Foroud, T., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24219 · Cited by 67
Self-citationDysregulated Wnt Signalling in the Alzheimer’s Brain
Aghaizu, N. D., Jin, H., & Whiting, P. J. (2020) · Brain Sciences · doi:10.3390/brainsci10120902 · Cited by 70
Midlife lipid and glucose levels are associated with Alzheimer's disease
Zhang, X., Tong, T., Chang, A., Ang, T. F. A., Tao, Q., Auerbach, S., Devine, S., Qiu, W. Q., Mez, J., Massaro, J., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12641 · Cited by 65
Self-citationMarini, S., Crawford, K., Morotti, A., Lee, M. J., Pezzini, A., Moomaw, C. J., Flaherty, M. L., Montaner, J., Roquer, J., Jimenez-Conde, J., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4519 · Cited by 68
Pathophysiology of Alzheimer’s Disease
Yarns, B. C., Holiday, K. A., Carlson, D. M., Cosgrove, C. K., & Melrose, R. J. (2022) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.07.003 · Cited by 68
Larusse, S., Roberts, J. S., Marteau, T. M., Katzen, H., Linnenbringer, E. L., Barber, M., Whitehouse, P., Quaid, K., Brown, T., Green, R. C., et al. (2005) · Genetics in Medicine · doi:10.1097/01.gim.0000151157.13716.6c · Cited by 67
Udeh-Momoh, C., & Watermeyer, T. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101459 · Cited by 67
Early and late onset Alzheimer’s disease patients have distinct patterns of white matter damage.
Canu, E., Frisoni, G. B., Agosta, F., Pievani, M., Bonetti, M., & Filippi, M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.09.021 · Cited by 67
Gooding, H. C., Linnenbringer, E. L., Burack, J. H., Roberts, J. S., Green, R. C., & Biesecker, B. B. (2006) · Patient Education and Counseling · doi:10.1016/j.pec.2006.03.002 · Cited by 66
“The risk of developing AD for a given individual with one or two e4 alleles varies with age, sex and ethnicity [3,4].”
BackgroundCommon human genetic variants of APOE impact murine COVID-19 mortality
Ostendorf, B. N., Patel, M. A., Bilanovic, J., Hoffmann, H.-H., Carrasco, S. E., Rice, C. M., & Tavazoie, S. F. (2022) · Nature · doi:10.1038/s41586-022-05344-2 · Cited by 69
Role of estrogen in women's Alzheimer's disease risk as modified by APOE
Valencia‐Olvera, A. C., Weng, J. M., Christensen, A., LaDu, M. J., & Pike, C. J. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13209 · Cited by 75
La Cunza, N., Tan, L. X., Thamban, T., Germer, C. J., Rathnasamy, G., Toops, K. A., & Lakkaraju, A. (2021) · JCI Insight · doi:10.1172/jci.insight.142254 · Cited by 65
Altmann, A., Scelsi, M. A., Shoai, M., de Silva, E., Aksman, L. M., Cash, D. M., Hardy, J., Schott, J. M., & Initiative, A. D. N. (2020) · Brain Communications · doi:10.1093/braincomms/fcz047 · Cited by 65
Kim, J., Park, M. H., Kim, E., Han, C., Jo, S. A., & Jo, I. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.9.2093 · Cited by 64
Raber, J., Arzy, S., Bertolus, J. B., Depue, B., Haas, H. E., Hofmann, S. G., Kangas, M., Kensinger, E., Lowry, C. A., Marusak, H. A., et al. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.03.015 · Cited by 62
Dementia care frameworks and assistive technologies for their implementation: a review
Koumakis, L., Chatzaki, C., Kazantzaki, E., Maniadi, E., & Tsiknakis, M. (2019) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2019.2892614 · Cited by 64
Genetics of Alzheimer’s disease: An East Asian perspective
Miyashita, A., Kikuchi, M., Hara, N., & Ikeuchi, T. (2023) · Journal of Human Genetics · doi:10.1038/s10038-022-01050-z · Cited by 64
Koch, G., Di Lorenzo, F., Loizzo, S., Motta, C., Travaglione, S., Baiula, M., Rimondini, R., Ponzo, V., Bonnì, S., Toniolo, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14204-3 · Cited by 64
Early-Onset Alzheimer Disease and Candidate Risk Genes Involved in Endolysosomal Transport
Kunkle, B. W., Vardarajan, B. N., Naj, A. C., Whitehead, P. L., Rolati, S., Slifer, S., Carney, R. M., Cuccaro, M. L., Vance, J. M., Gilbert, J. R., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.1518 · Cited by 58
Self-citationYang, J., Zhi, W., & Wang, L. (2024) · Molecules · doi:10.3390/molecules29122812 · Cited by 63
“Increasing age and the ApoE ε 4 genotype cause women to be prone to late-onset AD [129,130].”
BackgroundEffects of APOE Genotype on Brain Proteomic Network and Cell Type Changes in Alzheimer's Disease
Dai, J., Johnson, E. C. B., Dammer, E. B., Duong, D. M., Gearing, M., Lah, J. J., Levey, A. I., Wingo, T. S., & Seyfried, N. T. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00454 · Cited by 62
“The presence of an E2 allele lowers the odds to develop AD to 0.6 (Corder et al., 1994; Farrer et al., 1997).”
BackgroundInfluentialApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease
Li, Y., Macyczko, J. R., Liu, C.-C., & Bu, G. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.03.011 · Cited by 61
Parental family history of dementia in relation to subclinical brain disease and dementia risk
Wolters, F. J., van der Lee, S. J., Koudstaal, P. J., van Duijn, C. M., Hofman, A., Ikram, M. K., Vernooij, M. W., & Ikram, M. A. (2017) · Neurology · doi:10.1212/wnl.0000000000003871 · Cited by 59
Rajan, K. B., Barnes, L. L., Wilson, R. S., McAninch, E. A., Weuve, J., Sighoko, D., & Evans, D. A. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15059 · Cited by 59
Picard, C., Poirier, A., Bélanger, S., Labonté, A., Auld, D., Poirier, J., & on behalf of the PREVENT-AD Research Group (2019) · PLOS ONE · doi:10.1371/journal.pone.0220254 · Cited by 59
Structural brain changes in normal individuals with a maternal history of Alzheimer's
Berti, V., Mosconi, L., Glodzik, L., Li, Y., Murray, J., De Santi, S., Pupi, A., Tsui, W., & De Leon, M. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.01.001 · Cited by 58
“Several studies have shown that having a family history of LOAD is a major risk factor for developing the disease among cognitively normal (NL) individuals (Farrer et al., 1997).”
BackgroundGuo, J., Brickman, A. M., Manly, J. J., Reitz, C., Schupf, N., Mayeux, R. P., & Gu, Y. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12359 · Cited by 56
Lipid metabolism in Alzheimer’s disease
Zhu, T.-B., Zhang, Z., Luo, P., Wang, S.-S., Peng, Y., Chu, S.-F., & Chen, N.-H. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.11.012 · Cited by 55
ApoE e2 and aging-related outcomes in 379,000 UK Biobank participants
Kuo, C.-L., Pilling, L. C., Atkins, J. L., Kuchel, G. A., & Melzer, D. (2020) · Aging · doi:10.18632/aging.103405 · Cited by 55
“8) [6].”
Area-Gomez, E., Larrea, D., Pera, M., Agrawal, R. R., Guilfoyle, D. N., Pirhaji, L., Shannon, K., Arain, H. A., Ashok, A., Chen, Q., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-61142-8 · Cited by 55
Sex Difference in the Association of APOE4 with Memory Decline in Mild Cognitive Impairment
Wang, X., Zhou, W., Ye, T., Lin, X., Zhang, J., & Initiative, F. A. D. N. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-181234 · Cited by 51
In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS
Wildsmith, K. R., Basak, J. M., Patterson, B. W., Pyatkivskyy, Y., Kim, J., Yarasheski, K. E., Wang, J. X., Mawuenyega, K. G., Jiang, H., Parsadanian, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038013 · Cited by 54
“increases the risk of developing AD by either 3-fold (1 allele) or 12fold (2 alleles) [6], resulting in an earlier age of onset of AD [7,8].”
BackgroundBaker-Nigh, A. T., Mawuenyega, K. G., Bollinger, J. G., Ovod, V., Kasten, T., Franklin, E. E., Liao, F., Jiang, H., Holtzman, D., Cairns, N. J., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.721779 · Cited by 54
Günther, C., Hadeln, K. V., Müller-Thomsen, T., Alberici, A., Binetti, G., Hock, C., Nitsch, R. M., Stoppe, G., Reiss, J., Gal, A., et al. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.07.070 · Cited by 53
Vance, J. M., Farrer, L. A., Huang, Y., Cruchaga, C., Hyman, B. T., Pericak‐Vance, M. A., Goate, A. M., Greicius, M. D., Griswold, A. J., Haines, J. L., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26864 · Cited by 52
Self-citationXu, Z., Shen, X., Pan, W., & Initiative, F. T. A. D. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102312 · Cited by 51
“For example, both TOMM40 and APOE were known to be linked to Alzheimer’s disease [23–26].”
BackgroundAssociation of African Ancestry–Specific APOE Missense Variant R145C With Risk of Alzheimer Disease
Le Guen, Y., Raulin, A.-C., Logue, M. W., Sherva, R., Belloy, M. E., Eger, S. J., Chen, A., Kennedy, G., Kuchenbecker, L., O’Leary, J. P., et al. (2023) · JAMA · doi:10.1001/jama.2023.0268 · Cited by 50
Self-citationThe Interaction Between NF-κB and Estrogen in Alzheimer’s Disease
Mishra, P., Davies, D. A., & Albensi, B. C. (2023) · Molecular Neurobiology · doi:10.1007/s12035-022-03152-3 · Cited by 51
Sex differences in the genetic architecture of Alzheimer’s disease
Dumitrescu, L., Mayeda, E. R., Sharman, K., Moore, A. M., & Hohman, T. J. (2019) · Current Genetic Medicine Reports · doi:10.1007/s40142-019-0157-1 · Cited by 48
Paranjpe, M. D., Belonwu, S., Wang, J. K., Oskotsky, T., Gupta, A., Taubes, A., Zalocusky, K. A., Paranjpe, I., Glicksberg, B. S., Huang, Y., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.735611 · Cited by 49
Pontifex, M. G., Martinsen, A., Saleh, R. N. M., Harden, G., Tejera, N., Müller, M. M., Fox, C., Vauzour, D., & Minihane, A. M. (2021) · The FASEB Journal · doi:10.1096/fj.202002621rr · Cited by 51
Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
Homocysteine and cognitive performance: Modification by the ApoE genotype
Elias, M. F., Robbins, M. A., Budge, M. M., Elias, P. K., Dore, G. A., Brennan, S. L., Johnston, C., & Nagy, Z. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2007.10.021 · Cited by 45
Mormino, E. C. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9267-4 · Cited by 44
“Although the potential interaction between sex and Aβ in influencing downstream AD changes is currently understudied among amyloid imaging studies, it has been shown that women's elevated AD risk is modified by both the presence of the APOE4 allele and age (Duara et al. 1996; Farrer et al. 1997).”
Leveraging research into sex differences and steroid hormones to improve brain health
Lee, B. H., Eid, R. S., Hodges, T. E., Barth, C., & Galea, L. A. M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01061-0 · Cited by 48
“Possession of one or two APOE4 alleles confers a 5–15 times greater risk of developing Alzheimer disease, and 60% of individuals with Alzheimer disease possess an APOE4 allele 151 .”
Candidate gene studies of bipolar disorder
Jones, I., & Craddock, N. (2001) · Annals of Medicine · doi:10.3109/07853890108998753 · Cited by 44
Tong, L. M., Yoon, S. Y., Andrews-Zwilling, Y., Yang, A., Lin, V., Lei, H., & Huang, Y. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3815-15.2016 · Cited by 43
Chemparathy, A., Le Guen, Y., Chen, S., Lee, E.-G., Leong, L., Gorzynski, J. E., Jensen, T. D., Ferrasse, A., Xu, G., Xiang, H., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.01.008 · Cited by 43
“An APOE 4/ 4 individual of European ancestry has a sixteen-fold increase in AD risk and eighteen year earlier age at AD onset compared to a European ancestry individual carrying two copies of the more prevalent APOE 3 allele 4 .”
Do statins prevent Alzheimer's disease? A narrative review
Daneschvar, H. L., Aronson, M. D., & Smetana, G. W. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.08.012 · Cited by 42
Olarte, L., Schupf, N., Lee, J. H., Tang, M.-X., Santana, V., Williamson, J., Maramreddy, P., Tycko, B., & Mayeux, R. (2006) · Archives of Neurology · doi:10.1001/archneur.63.11.1586 · Cited by 42
Orth, M., Weng, W., Funke, H., Steinmetz, A., Assmann, G., Nauck, M., Dierkes, J., Ambrosch, A., Weisgraber, K. H., Mahley, R. W., et al. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.5.1306 · Cited by 42
Luo, R., Fan, Y., Yang, J., Ye, M., Zhang, D., Guo, K., Li, X., Bi, R., Xu, M., Yang, L.-X., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00748-4 · Cited by 41
Marano, E. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.022285 · Cited by 40
Hobel, Z., ageing, F. T. A. D. N. I. A. T. A. I. B. A. L. F. S. O., Isenberg, A. L., Raghupathy, D., Mack, W., & Pa, J. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180859 · Cited by 40
Kamboh, M. I., Aston, C. E., Perez-Tur, J., Kokmen, E., Ferrell, R. E., Hardy, J., & DeKosky, S. T. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00129-9 · Cited by 40
Henningfield, C. M., Arreola, M. A., Soni, N., Spangenberg, E. E., & Green, K. N. (2022) · Glia · doi:10.1002/glia.24105 · Cited by 40
Genetics and Functional Imaging: Effects of APOE, BDNF, COMT, and KIBRA in Aging
Papenberg, G., Salami, A., Persson, J., Lindenberger, U., & Bäckman, L. (2015) · Neuropsychology Review · doi:10.1007/s11065-015-9279-8 · Cited by 39
“The ε4 allele is the strongest genetic risk factor for AD, such that the presence of one or two ε4 alleles is associated with higher risk of developing AD in a dose-dependent manner (Blacker et al. 1997; Farrer et al. 1997; Okuizumi et al. 1995).”
BackgroundWang, S., Li, B., Li, J., Cai, Z., Hugo, C., Sun, Y. E., Qian, L., Julia, T. C. W., Chui, H. C., Dikeman, D., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00802-7 · Cited by 55
“Apolipoprotein E4 allele (APOE4) is the strongest genetic risk factor for late-onset AD [16, 17].”
Aslam, M. M., Fan, K.-H., Lawrence, E., Bedison, M. A., Snitz, B. E., DeKosky, S. T., Lopez, O. L., Feingold, E., & Kamboh, M. I. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02170-4 · Cited by 39
Pettigrew, C., Soldan, A., Moghekar, A., Wang, M.-C., Gross, A. L., O’Brien, R., & Albert, M. (2015) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2015.09.024 · Cited by 38
Stocker, H. R., Nabers, A., Perna, L., Möllers, T., Rujescu, D., Hartmann, A. M., Holleczek, B., Schöttker, B., Gerwert, K. B., & Brenner, H. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.08.189 · Cited by 36
Longitudinal association of apolipoprotein E and sleep with incident dementia
Palpatzis, E., Bass, N. J., Jones, R., & Mukadam, N. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12439 · Cited by 39
The presence of apoE4, not the absence of apoE3, contributes to AD pathology
Teter, B., Raber, J., Nathan, B., & Crutcher, K. A. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4305 · Cited by 37
Neighborhood greenspace and cognition: The cardiovascular health study
Godina, S., Rosso, A. L., Hirsch, J. A., Besser, L. M., Lovasi, G. S., Donovan, G. H., Garg, P. K., Platt, J. M., Fitzpatrick, A. L., López, O. L., et al. (2023) · Health & Place · doi:10.1016/j.healthplace.2022.102960 · Cited by 34
Apolipoprotein E isoform-dependent effects on the processing of Alzheimer's amyloid-β
Chai, A. B., Lam, H. H. J., Kockx, M., & Gelissen, I. C. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158980 · Cited by 41
Fragment-Based Discovery of an Apolipoprotein E4 (apoE4) Stabilizer
Petros, A. M., Korepanova, A., Jakob, C. G., Qiu, W., Panchal, S. C., Wang, J., Dietrich, J. D., Brewer, J. T., Pohlki, F., Kling, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00178 · Cited by 32
Kloske, C. M., Belloy, M. E., Blue, E. E., Bowman, G. R., Carrillo, M. C., Chen, X., Chiba‐Falek, O., Davis, A. A., Paolo, G. D., Garretti, F., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13877 · Cited by 33
Jiang, Y., Uhm, H., Ip, F. C., Ouyang, L., Lo, R. M. N., Cheng, E. Y. L., Cao, X., Tan, C. M. C., Law, B. C. H., Ortiz‐Romero, P., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13676 · Cited by 36
Apolipoprotein E ε4-related thickening of the cerebral cortex modulates selective attention
Espeseth, T., Westlye, L. T., Walhovd, K. B., Fjell, A. M., Endestad, T., Rootwelt, H., & Reinvang, I. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.12.027 · Cited by 32
Preman, P., Moechars, D., Fertan, E., Wolfs, L., Serneels, L., Shah, D., Lamote, J., Poovathingal, S., Snellinx, A., Mancuso, R., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00162-7 · Cited by 32
Method for the simultaneous quantitation of apolipoprotein E isoforms using tandem mass spectrometry
Wildsmith, K. R., Han, B., & Bateman, R. J. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.07.049 · Cited by 31
Some evolutionary perspectives on Alzheimer's disease pathogenesis and pathology
Glass, D. J., & Arnold, S. E. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2408 · Cited by 29
Genetic and polygenic risk score analysis for Alzheimer's disease in the Chinese population
Zhou, X., Chen, Y., Ip, F. C. F., Lai, N. C. H., Li, Y. Y. T., Jiang, Y., Zhong, H., Chen, Y., Zhang, Y., Ma, S., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12074 · Cited by 33
Evidence for three loci modifying age‐at‐onset of Alzheimer's disease in early‐onset PSEN2 families
Marchani, E. E., Bird, T. D., Steinbart, E. J., Rosenthal, E., Yu, C., Schellenberg, G. D., & Wijsman, E. M. (2010) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31072 · Cited by 29
“The APOE e4 allele reduces age-at-onset in a dose-dependent manner in both LOAD [Saunders et al., 1993; Strittmatter et al., 1993; Farrer et al., 1997] and some EOAD pedigrees [Pastor et al., 2003; Wijsman et al., 2005].”
BackgroundBond, G. E., Burr, R., Mccurry, S. M., Rice, M. M., Borenstein, A. R., Kukull, W. A., Teri, L., Bowen, J. D., Mccormick, W. C., & Larson, E. B. (2004) · Journal of Aging and Health · doi:10.1177/0898264304268587 · Cited by 30
The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment
Zieneldien, T., Kim, J., & Cao, C. (2022) · Geriatrics · doi:10.3390/geriatrics7020024 · Cited by 29
Age stratification corrects bias in estimated hazard of APOE genotype for Alzheimer's disease
Liu, L., & Caselli, R. J. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.09.006 · Cited by 29
Evaluation of respiratory chain activity in lymphocytes of patients with Alzheimer disease
Feldhaus, P., Fraga, D. B., Ghedim, F. V., De Luca, R. D., Bruna, T. D., Heluany, M., Matos, M. P., Ferreira, G. K., Jeremias, I. C., Heluany, C., et al. (2011) · Metabolic Brain Disease · doi:10.1007/s11011-011-9253-y · Cited by 27
“The most common risk factors for AD include age (Atamina and Frey 2007), a family history of the disease in first-degree relatives ( Farrer et al. 1997 ), the presence of ApoE4 (Nitrini 1999; Maruszak and Zekanowki 2011), and a low educational level (Cummings et al. 2004).”
BackgroundProspects of Saffron and its Derivatives in Alzheimer’s Disease
Zandi, N., Pazoki, B., Roudsari, N. M., Lashgari, N., Jamshidi, V., Momtaz, S., Abdolghaffari, A. H., & Akhondzadeh, S. (2021) · Archives of Iranian Medicine · doi:10.34172/aim.2021.35 · Cited by 25
Saunders, T. S., Jenkins, N. D., Blennow, K., Ritchie, C. W., & Terrera, G. M. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104241 · Cited by 28
Günaydin, C., Sondhi, D., Kaminsky, S. M., Lephart, H. C., Leopold, P. L., Hackett, N. R., Khanna, R., & Crystal, R. G. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.003 · Cited by 26
Sapkota, B., Subramanian, A., Priamvada, G., Finely, H., Blackett, P. R., Aston, C. E., & Sanghera, D. K. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.07.025 · Cited by 25
“…risk of coronary artery disease (CAD) (Bennet et al., 2007; Chaudhary et al., 2012; Song, Stampfer, & Liu, 2004; Stengard, Weiss, & Sing, 1998; Zhang et al., 2014) and late-onset of Alzheimer's disease (Farrer et al., 1997; Kamboh, Sanghera, Ferrell, & DeKosky, 1995; Strittmatter et al., 1993).”
Class I HDAC inhibition is a novel pathway for regulating astrocytic apoE secretion
Dresselhaus, E., Duerr, J. M., Vincent, F., Sylvain, E. K., Beyna, M., Lanyon, L. F., LaChapelle, E., Pettersson, M., Bales, K. R., & Ramaswamy, G. (2018) · PLOS ONE · doi:10.1371/journal.pone.0194661 · Cited by 25
Internal carotid artery dissection
Besselmann, M., Vennemann, B., Lowens, S., Ringelstein, E. B., & Stögbauer, F. (2000) · Neurology · doi:10.1212/wnl.54.2.442 · Cited by 21
Use of Genetic Variation as Biomarkers for Alzheimer's Disease
Reitz, C., & Mayeux, R. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04945.x · Cited by 24
Kitzlerová, E., Fišar, Z., Lelková, P., Jirák, R., Zvěřová, M., Hroudová, J., Manukyan, A., Martásek, P., & Raboch, J. (2018) · Medical Science Monitor · doi:10.12659/msm.907202 · Cited by 21
Ma, C., Wang, J., Zhang, J., Chen, K., Li, X., Shu, N., Chen, Y., Liu, Z., & Zhang, Z. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0224-5 · Cited by 21
Gao, L., Chen, J., Gu, L., Shu, H., Wang, Z., Liu, D., Yan, Y., & Zhang, Z. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00256 · Cited by 21
Ready, R. E., Baran, B., Chaudhry, M., Schatz, K., Gordon, J., & Spencer, R. M. C. (2011) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317511421921 · Cited by 21
Fan, K., Francis, L., Aslam, M. M., Bedison, M. A., Lawrence, E., Acharya, V., Snitz, B. E., Ganguli, M., DeKosky, S. T., Lopez, O. L., et al. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.11.007 · Cited by 21
Reas, E. T., Triebswetter, C., Banks, S. J., & McEvoy, L. K. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01380-w · Cited by 21
“Compared to ε3 homozygotes, individuals with one or two ε4 alleles harbor approximately 3 and 15 times increased risk, respectively, whereas carriers of the protective ε2 allele have an estimated 1.7 times decreased risk [1].”
BackgroundInfluentialToniutto, P., Fabris, C., Fumo, E., Apollonio, L., Caldato, M., Mariuzzi, L., Avellini, C., Minisini, R., & Pirisi, M. (2004) · American Journal of Clinical Pathology · doi:10.1309/ylexqa2r6r2n95ju · Cited by 19
Huggins, L. K. L., Min, S. H., Kaplan, S., Wei, J., Welsh-Bohmer, K., & Xu, H. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-221167 · Cited by 18
Association between apolipoprotein E genotype and cancer susceptibility: a meta-analysis
Anand, R., Prakash, S. S., Veeramanikandan, R., & Kirubakaran, R. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1634-2 · Cited by 18
Metadata
- Authors
- Farrer, L. A.
- Corresponding author
- Farrer, Lindsay A.
- ORCID
- Farrer, Lindsay A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1997-10-22
- Volume
- 278
- Issue
- 16
- Pages
- 1349
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W7028228764
- Cited by
- 124
- References
- 0
- Citations by year
- 2026: 16 · 2025: 8 · 2024: 6 · 2023: 12 · 2022: 12 · 2021: 11 · 2020: 12 · 2019: 7 · 2018: 5 · 2017: 7 · 2016: 3 · 2015: 5 · 2014: 4 · 2013: 1 · 2012: 4
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, Alzheimer's disease, genetic risk, age of onset, sex differences, ethnic differences, African Americans, Hispanic population, Japanese population, genetic heterogeneity, dementia risk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
